Hong Chien-Hui, Lin Shang-Hung, Lee Chih-Hung
Department of Dermatology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, R.O.C.
Department of Dermatology, National Yang-Ming University College of Medicine, Taipei, Taiwan, R.O.C.
In Vivo. 2019 May-Jun;33(3):793-800. doi: 10.21873/invivo.11541.
Mycosis fungoides (MF) is indolent, but may disseminate to leukemia. We reported that C-C motif chemokine ligand 21 (CCL21) is associated with MF invasion and progression. Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), a long noncoding RNA, is associated with several cancer types, however, how it interacts with CCL21 to regulate MF progression, remains unclear.
Expression of long noncoding RNAs MALAT1, antisense noncoding RNA in the INK4 locus (ANRIL), Hox antisense intergenic RNA (HOTAIR), highly up-regulated in liver cancer RNA (HULC), and leukemia-associated non-coding insulin-like growth factor 1 receptor activator RNA 1 (LUNAR1) in tissues from MF was studied using polymerase chain reaction and RNA interference in MF cell line MyLa were used to address this question.
Expression of MALAT1 was selectively increased in MF tissues. C-C Chemokine receptor type 7 (CCR7) expression was found to be increased in MyLa cells. CCL21 was found not only to mediate migration, but also to enhance MALAT1 and mammalian target of rapamycin (mTOR) activation in MyLa cells. Knockdown of MALAT1 abrogated CCL21-mediated migration, but not mTOR activation. In contrast, mTOR inhibition reduced CCL21-mediated migration and MALAT1 expression.
CCL21 induced mTOR activation in MyLa cells, followed by expression of MALAT1, causing cell migration. MALAT1 and mTOR are potential therapeutic targets for MF.
蕈样肉芽肿(MF)病程进展缓慢,但可能会发展为白血病。我们之前报道过,C-C基序趋化因子配体21(CCL21)与MF的侵袭和进展相关。转移相关的肺腺癌转录本1(MALAT1)是一种长链非编码RNA,与多种癌症类型相关,然而,其如何与CCL21相互作用以调节MF进展仍不清楚。
采用聚合酶链反应研究MF组织中长链非编码RNA MALAT1、INK4基因座反义非编码RNA(ANRIL)、Hox反义基因间RNA(HOTAIR)、肝癌中高度上调的RNA(HULC)以及白血病相关的非编码胰岛素样生长因子1受体激活剂RNA 1(LUNAR1)的表达,并利用RNA干扰MF细胞系MyLa来解决这个问题。
MALAT1在MF组织中的表达选择性增加。发现C-C趋化因子受体7型(CCR7)在MyLa细胞中的表达增加。不仅发现CCL21可介导MyLa细胞迁移,还可增强MALAT1和雷帕霉素哺乳动物靶蛋白(mTOR)的激活。敲低MALAT1可消除CCL21介导的迁移,但不影响mTOR的激活。相反,mTOR抑制可减少CCL21介导的迁移和MALAT1的表达。
CCL21在MyLa细胞中诱导mTOR激活,随后导致MALAT1表达,从而引起细胞迁移。MALAT1和mTOR是MF潜在的治疗靶点。